Fast Five Quiz: Diabetic Nephropathy Management

A. Brent Alper, Jr, MD, MPH


April 24, 2020

Alpha-glucosidase inhibitors slow the absorption of glucose following a meal. However, they have not been studied in patients with advanced kidney disease and are not recommended in this setting.

Approximately 80% of the dipeptidyl peptidase–4 inhibitor sitagliptin is cleared by the kidney; therefore, the standard dose of 100 mg daily should be reduced in patients with reduced GFRs. With an estimated GFR of ≥ 30 to < 50 mL/min/1.73 m2, the recommended dose is 50 mg once daily. For patients with an estimated GFR < 30 mL/min/1.73 m2, a dose of 25 mg once daily is advised.

In the multicenter, randomized, double-blind, placebo-controlled CREDENCE trial, which enrolled 4401 patients with diabetic nephropathy, the sodium-glucose cotransporter 2 inhibitor canagliflozin was associated with a 30% reduction in the risk of progression to end-stage kidney disease; canagliflozin also significantly decreased the chances for major cardiovascular events. Canagliflozin is not approved for use in patients with T1DM.

The injectable incretin mimetic liraglutide is not metabolized by the kidney, and no dose adjustment is necessary in patients with a decreased GFR, including in patients with ESRD; however, data in this population are limited, and the manufacturer advises using caution in initiating or increasing the dose in patients with kidney disease.

Learn more about the antidiabetic agents and diabetic nephropathy.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.